Literature DB >> 23397588

Outcomes after interdisciplinary management of 7 patients with Askin tumor.

Alireza Basharkhah1, Jasmin Pansy, Christian Urban, Michael E Höllwarth.   

Abstract

PURPOSE: Askin tumors are rare but highly malignant chest wall tumors, which require multimodal therapy including often extensive resection of the thoracic wall. This study evaluated the outcome of Askin tumor in seven patients with an interdisciplinary approach.
METHODS: Patients' records, treated between 1994 and 2011, were reviewed retrospectively. Seven patients (three male, four female; mean age 12.3 years; range 2-21 years) were included. All patients received neoadjuvant chemotherapy. After reduction of initial tumor volume, radical tumor resection and thoracic wall reconstruction were performed. All survivors were evaluated in 2011 by clinical examination and lung function test.
RESULTS: Five-year survival rate in our group of patients is 86 % and overall survival is 71 %. There were two mortalities. One patient passed away 7.5 years after the primary management, mainly attributed to tumor progression, which demanded aggressive surgical procedures and irradiation. Another patient died 18 months after the first diagnosis after several surgical interventions for recurrent multiple pulmonary metastases. Three years after the first diagnosis, one patient suffered from clear cell sarcoma of the contralateral kidney and developed a local recurrence of Askin 1 year later. The large chest wall defects arising after surgery have been successfully reconstructed using combination of latissimus dorsi muscle flaps and biomaterials.
CONCLUSION: Data of pediatric patients with Askin tumor is scarce. Analysis of our seven patient series indicates that improved outcomes (71 % over all survival rate and 86 % 5-year survival rate) can be achieved by aggressive interdisciplinary management including radical surgery and chemotherapy. Chest wall stability can be achieved by utilization of local muscle flaps and biomaterials to cover surgical chest wall defects.

Entities:  

Mesh:

Year:  2013        PMID: 23397588     DOI: 10.1007/s00383-013-3272-1

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  23 in total

1.  Preoperative chemotherapy is essential for conservative surgery of Askin tumors.

Authors:  G Veronesi; L Spaggiari; T De Pas; P G Solli; F De Braud; G P Catalano; G Curigliano; F Leo; U Pastorino
Journal:  J Thorac Cardiovasc Surg       Date:  2003-02       Impact factor: 5.209

2.  Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study.

Authors:  M E Nesbit; E A Gehan; E O Burgert; T J Vietti; A Cangir; M Tefft; R Evans; P Thomas; F B Askin; J M Kissane
Journal:  J Clin Oncol       Date:  1990-10       Impact factor: 44.544

3.  Prognostic factors and outcome in Askin-Rosai tumor: a review of 104 patients.

Authors:  Siddhartha Laskar; Chandrika Nair; Suman Mallik; Gaurav Bahl; Suresh Pai; Tanuja Shet; Tejpal Gupta; Brijesh Arora; Ashish Bakshi; C S Pramesh; Rajesh Mistry; Sajid Qureshi; Seema Medhi; Nirmala Jambhekar; Purna Kurkure; Shripad Banavali; Mary Ann Muckaden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-14       Impact factor: 7.038

4.  Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors.

Authors:  A Aurias; C Rimbaut; D Buffe; J M Zucker; A Mazabraud
Journal:  Cancer Genet Cytogenet       Date:  1984-05

5.  Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.

Authors:  Christine Juergens; Claire Weston; Ian Lewis; Jeremy Whelan; Michael Paulussen; Odile Oberlin; Jean Michon; Andreas Zoubek; Herbert Juergens; Alan Craft
Journal:  Pediatr Blood Cancer       Date:  2006-07       Impact factor: 3.167

6.  Latissimus dorsi muscle-flap over Gore-Tex patch for coverage of large thoracic defects in paediatric Ewing sarcoma.

Authors:  Christophe Gapany; Wassim Raffoul; Pierre-Yves Zambelli; Jean-Marc Joseph
Journal:  Pediatr Blood Cancer       Date:  2009-05       Impact factor: 3.167

7.  Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80.

Authors:  M Salzer-Kuntschik; G Delling; G Beron; R Sigmund
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

8.  In vitro proliferative advantage of bone marrow cells with tetrasomy 8 in Ewing sarcoma.

Authors:  L Trakhtenbrot; Y Neumann; M Mandel; A Toren; N Gipsh; E Rosner; G Rechavi; F Brok-Simoni
Journal:  Cancer Genet Cytogenet       Date:  1996-09

9.  EWS rearrangement in Ewing's sarcoma and peripheral neuroectodermal tumor. Molecular detection and correlation with cytogenetic analysis and MIC2 expression.

Authors:  M Ladanyi; R Lewis; P Garin-Chesa; W J Rettig; A G Huvos; J H Healey; S C Jhanwar
Journal:  Diagn Mol Pathol       Date:  1993-09

10.  Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy.

Authors:  Robert C Shamberger; Michael P LaQuaglia; Mark C Gebhardt; James R Neff; Nancy J Tarbell; Karen C Marcus; Scott L Sailer; Richard B Womer; James S Miser; Paul S Dickman; Elizabeth J Perlman; Meenakshi Devidas; Stephen B Linda; Mark D Krailo; Holcombe E Grier; Linda Granowetter
Journal:  Ann Surg       Date:  2003-10       Impact factor: 12.969

View more
  1 in total

1.  Interdisciplinary Radical "En-Bloc" Resection of Ewing Sarcoma of the Chest Wall and Simultaneous Chest Wall Repair Achieves Excellent Long-Term Survival in Children and Adolescents.

Authors:  Alireza Basharkhah; Herwig Lackner; Anna Karastaneva; Marko Bergovec; Stephan Spendel; Christoph Castellani; Erich Sorantin; Martin Benesch; Bernadette Liegl-Atzwanger; Freyja-Maria Smolle-Jüttner; Christian Urban; Michael Höllwarth; Georg Singer; Holger Till
Journal:  Front Pediatr       Date:  2021-03-15       Impact factor: 3.418

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.